# US 2012/0237626 A9 · Profiles of lipid proteins and inhibiting HMG-CoA reductase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237626 A9
- Document ID: US20120237626A9
- Status: Published application
- Kind: A9
- Application number: 11/034,505
- Filed: 2005-01-13
- Published: 2012-09-20
- Earliest claimed: 2000-12-05
- Inventors: Afa Palu; Claude Jensen; Mian Wang; Bing-Nan Zhou; Stephen Story
- Web page: https://patentgrep.com/patent/US20120237626A9

## CPC

- A61K 36/746: Morinda
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention comprises methods and compositions for improving profiles of lipid proteins, reducing low-density lipoprotein levels, increasing high-density lipoprotein levels, decreasing the absorption of fatty acids across the intestinal epithelium and inhibiting HMG-CoA Reductase in living organisms utilizing Morinda citrifolia L activity in mammals, including humans.

## Claims

### Claim 1

A formulation adapted for improving lipoprotein profiles in mammals comprising: at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein said Morinda citrifolia product is used with a carrier medium.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein said processed Morinda citrifolia product comprises a processed Morinda citrifolia selected from a group consisting of: extract from the leaves of Morinda citrifolia, leaf hot water extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf ethanol extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf steam distillation extract present in an amount by weight between about 0.1 and 50 percent, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze concentrated Morinda citrifolia fruit juice, and evaporated concentration of Morinda citrifolia fruit juice.

### Claim 4 (depends on 1)

The formulation of claim 1, comprising at least one active ingredient selected from a group consisting of quercetin, rutin, scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacanthal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid, and putative proxeronines.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein said formulation is administered to a patient by at least one method selected from a list consisting of orally, intravenously, and systemically.

### Claim 6 (depends on 1)

The formulation of claim 1, further comprising at least one other ingredient selected from the group consisting of processed Morinda citrifolia products, food supplements, dietary supplements, other fruit juices, other natural ingredients, natural flavorings, artificial flavorings, natural sweeteners, artificial sweeteners, natural coloring, and artificial coloring.

### Claim 7

A formulation comprising:
at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect mammals in a way selected from a group consisting of: inhibit HMG-CoA Reductase, reduce low-density lipoprotein levels, increase high-density lipoprotein levels, protect by prophylactic treatment from tobacco smoke-induced cardiac disease, and decrease the absorption of fatty acids across the intestinal epithelium.

### Claim 8

A method for improving lipoprotein profiles in mammals comprising the step of:
administering a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent.

### Claim 9 (depends on 8)

The method of claim 8, wherein two ounces of the formulation is administered twice daily.

### Claim 10 (depends on 8)

The method of claim 8, wherein said Morinda citrifolia product is administered with a carrier medium.

### Claim 11 (depends on 8)

The method of claim 8, wherein said processed Morinda citrifolia product comprises a processed Morinda citrifolia selected from a group consisting of: extract from the leaves of Morinda citrifolia, leaf hot water extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf ethanol extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf steam distillation extract present in an amount by weight between about 0.1 and 50 percent, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze concentrated Morinda citrifolia fruit juice, and evaporated concentration of Morinda citrifolia fruit juice.

### Claim 12 (depends on 8)

The method of claim 8, wherein the formulation comprises at least one active ingredient selected from a group consisting of quercetin, rutin, scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacanthal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid, and putative proxeronines.

### Claim 13 (depends on 8)

The method of claim 8, wherein the formulation further comprising at least one other ingredient selected from the group consisting of processed Morinda citrifolia products, food supplements, dietary supplements, other fruit juices, other natural ingredients, natural flavorings, artificial flavorings, natural sweeteners, artificial sweeteners, natural coloring, and artificial coloring.

### Claim 14 (depends on 8)

The method of claim 8, further comprising the step of concurrently administering said formulation with another medication designed to improve lipoprotein profiles and its associated conditions, wherein said formulation increases the efficacy of said medication.

### Claim 15 (depends on 8)

The method of claim 8, wherein said formulation is administered in an amount between about 1 teaspoon and 2 ounces at least twice daily on an empty stomach each day.

### Claim 16

A method of treating mammals comprising:
administering a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect mammals in a way selected from a group consisting of: inhibit HMG-CoA Reductase, reduce low-density lipoprotein levels, increase high-density lipoprotein levels, to protect by prophylactic treatment from tobacco smoke-induced cardiac disease, and decrease the absorption of fatty acids across the intestinal epithelium.
